Quick Answer
Vera Therapeutics, Inc. reported Net Income of -$299.62 million for fiscal year 2025.
Vera Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$299.62M -96.9% |
-$152.15M -58.5% |
-$95.99M -7.8% |
-$89.06M -173.1% |
-$32.61M +38.9% |
-$53.41M |
| Diluted EPS | -$4.66 -69.5% |
-$2.75 -22.2% |
-$2.25 +32.8% |
-$3.35 -37.9% |
-$2.43 | — |
| Total Assets | $734.73M +12.1% |
$655.68M +273.5% |
$175.55M +33.6% |
$131.44M +56.9% |
$83.75M +53.5% |
$54.55M |
| Cash and Equivalents | $354.73M +282.9% |
$92.65M +102.8% |
$45.68M +5.1% |
$43.46M -45.5% |
$79.67M +48.5% |
$53.65M |
| Long-Term Debt | $74.84M +47.6% |
$50.69M +1.6% |
$49.88M +101.0% |
$24.81M +404.0% |
$4.92M | $0.00 |
| Stockholders Equity | $604.52M +4.7% |
$577.15M +467.6% |
$101.69M +32.2% |
$76.91M +10.5% |
$69.59M +177.9% |
-$89.35M -144.5% |
| R&D Expense | $215.26M +70.6% |
$126.17M +61.3% |
$78.22M +13.4% |
$68.99M +206.9% |
$22.48M -50.3% |
$45.21M |
| Operating Income | -$315.47M -88.7% |
-$167.17M -63.9% |
-$102.01M -12.2% |
-$90.90M -164.2% |
-$34.40M +34.1% |
-$52.24M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$80.29M | -72.2% | -4.9% |
| Diluted EPS | September 30, 2025 | -$1.26 | -48.2% | -5.0% |
| Total Assets | September 30, 2025 | $517.50M | +40.4% | -10.5% |
| Cash and Equivalents | September 30, 2025 | $57.77M | +112.0% | +17.6% |
| Long-Term Debt | September 30, 2025 | $74.65M | +47.9% | +0.2% |
| Stockholders Equity | September 30, 2025 | $398.88M | +38.0% | -14.8% |
| R&D Expense | September 30, 2025 | $56.47M | +40.1% | -3.0% |
| Operating Income | September 30, 2025 | -$83.93M | -68.5% | -4.7% |
- Vera Therapeutics, Inc. reported Net Income of -$299.62 million for fiscal year 2025.
- Vera Therapeutics, Inc. showed a decrease of -96.9% in Net Income compared to the prior fiscal year.
- Vera Therapeutics, Inc. reported Diluted EPS of $4.66 per share (loss) for fiscal year 2025.
- Vera Therapeutics, Inc. showed a decrease of -69.5% in Diluted EPS compared to the prior fiscal year.
- Vera Therapeutics, Inc. reported Total Assets of $734.73 million for fiscal year 2025.
- Vera Therapeutics, Inc. showed an increase of +12.1% in Total Assets compared to the prior fiscal year.
- Vera Therapeutics, Inc. reported Cash and Equivalents of $354.73 million for fiscal year 2025.
- Vera Therapeutics, Inc. showed an increase of +282.9% in Cash and Equivalents compared to the prior fiscal year.
- Vera Therapeutics, Inc. reported Long-Term Debt of $74.84 million for fiscal year 2025.
- Vera Therapeutics, Inc. showed an increase of +47.6% in Long-Term Debt compared to the prior fiscal year.
- Vera Therapeutics, Inc. reported Stockholders Equity of $604.52 million for fiscal year 2025.
- Vera Therapeutics, Inc. showed an increase of +4.7% in Stockholders Equity compared to the prior fiscal year.
- Vera Therapeutics, Inc. reported R&D Expense of $215.26 million for fiscal year 2025.
- Vera Therapeutics, Inc. showed an increase of +70.6% in R&D Expense compared to the prior fiscal year.
- Vera Therapeutics, Inc. reported Operating Income of -$315.47 million for fiscal year 2025.
- Vera Therapeutics, Inc. showed a decrease of -88.7% in Operating Income compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: